AlphaLabs is the intelligence layer for biotech \u2014 tracking companies, analyzing emerging research, and surfacing where the next breakthrough drugs are forming before they reach the market.
One platform combining market intelligence, biological simulation, and AI-driven opportunity scoring \u2014 purpose-built for biotech.
An interactive network graph showing relationships between biopharma, DeSci, and AI drug discovery companies — partnerships, competition, and capital flows in one view.
Run multi-agent in-silico peptide candidate searches against any target profile. Watch the evolution of each candidate across rounds in an interactive 3D timeline.
AI-scored investment opportunities ranked by analyst consensus, fundamentals, technicals, and network position. DeSci companies get on-chain signal weighting.
Every morning: top movers, sector performance across Peptide Pharma, Clinical Biotech, AI Discovery, and DeSci — with momentum leaders and AI signals.
Identify the highest-leverage nodes in the biotech network — companies whose disruption ripples furthest downstream through the drug development pipeline.
Simulate what happens when a key company fails, merges, or pivots. See which partners, competitors, and dependencies are exposed and to what degree.
We combine real-time market data, simulated biological signals, and network intelligence to make drug discovery observable.
We map 20+ companies across six sectors into a live network — capturing every supply relationship, investment tie, and competitive dynamic.
Each node is scored on analyst consensus, fundamentals, technicals, and network centrality — updated from live market data.
Our multi-agent Molecule Lab generates and evolves peptide candidates against company-specific target profiles using in-silico heuristics.
Opportunity Finder surfaces ranked investment signals with full scoring transparency — before catalysts become consensus.
Turn drug discovery into something observable, understandable, and investable.
Enter AlphaLabs